CRP and Crohn disease: However, it is also noteworthy that patients with baseline characteristics indicating greater Crohn's disease severity according to objective measures, such as greater baseline CRP or fecal calprotectin levels, appeared to benefit more from ustekinumab IV reinduction than those with lower disease severity.